Information and Resources
National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) issued new guidelines on understanding and managing immunotherapy-related toxicities.
Read more on curetuday.com HERE
February 14, 2018 – Today the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada, also previously called ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). This clinical setting is when men who are being treated with Androgen deprivation therapy (ADT) see their PSA levels begin to rise, but no metastases are visible yet on scans. There were previously no FDA-approved treatments for non-metastatic CRPC, and patients typically continued to receive ADT, despite its diminishing benefit.
To read more about this, click HERE.
The 2018 Genitourinary Cancers Symposium event featured groundbreaking research among members of the cancer care and research community who diagnose, treat, and study genitourinary malignancies.
Click on the below links to view conference proceedings on
From the 2018 Genitourinary Cancers Symposium:
Diagnosis and treatment of advanced prostate cancer continue to evolve. A better understanding of the genomics of this malignancy, as well as improved imaging techniques and developments of new therapeutics, are pushing that evolution. Several experts discussed the changing field of advanced prostate cancer management on February 8.
Read more here
PCF reports that U.S. Food and Drug Administration has approved Abiraterone + Prednisone combination for men with metastatic high-risk castration-sensitive prostate cancer (CSPC). The approval is based on the results of the LATITUDE study.
Read more on pcf.org here
By Ravi A. Madan, MD, and William L. Dahut, MD
Although immunotherapies are poised to permanently reshape treatment for bladder and kidney cancers, immune-based therapeutics research in prostate cancer has stagnated. There is immunotherapy available for prostate cancer, however, the delayed effects of treatment and the rare effect on prostate-specific antigen (PSA) levels have generated less enthusiasm compared with the rapid and sustained responses in some patients with bladder and kidney cancers who have been treated with immune checkpoint inhibitors. In addition, recent negative results of some trials have raised more concerns about the lack of potential for immunotherapy in prostate cancer. Nonetheless, several ongoing studies of immune checkpoint inhibitor combinations are potentially defining a course for immunotherapy development.
Read the article here